1. Home
  2. IAF vs NTHI Comparison

IAF vs NTHI Comparison

Compare IAF & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Australia Equity Fund Inc.

IAF

abrdn Australia Equity Fund Inc.

HOLD

Current Price

$12.69

Market Cap

120.7M

Sector

Finance

ML Signal

HOLD

NTHI

NeOnc Technologies Holdings Inc.

HOLD

Current Price

$5.04

Market Cap

139.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IAF
NTHI
Founded
1985
2008
Country
United States
United States
Employees
N/A
5
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.7M
139.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IAF
NTHI
Price
$12.69
$5.04
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
19.0K
77.5K
Earning Date
01-01-0001
05-19-2026
Dividend Yield
11.44%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.36
$3.20
52 Week High
$14.54
$12.99

Technical Indicators

Market Signals
Indicator
IAF
NTHI
Relative Strength Index (RSI) 51.11 57.73
Support Level $12.41 $4.17
Resistance Level $13.11 $5.90
Average True Range (ATR) 0.26 0.60
MACD 0.04 0.09
Stochastic Oscillator 49.17 73.77

Price Performance

Historical Comparison
IAF
NTHI

About IAF abrdn Australia Equity Fund Inc.

Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.

About NTHI NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.

Share on Social Networks: